289 related articles for article (PubMed ID: 8622030)
21. Treatment of small cell lung cancer in the elderly.
Shepherd FA; Amdemichael E; Evans WK; Chalvardjian P; Hogg-Johnson S; Coates R; Paul K
J Am Geriatr Soc; 1994 Jan; 42(1):64-70. PubMed ID: 8277118
[TBL] [Abstract][Full Text] [Related]
22. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis.
Spiro SG; James LE; Rudd RM; Trask CW; Tobias JS; Snee M; Gilligan D; Murray PA; Ruiz de Elvira MC; O'Donnell KM; Gower NH; Harper PG; Hackshaw AK;
J Clin Oncol; 2006 Aug; 24(24):3823-30. PubMed ID: 16921033
[TBL] [Abstract][Full Text] [Related]
23. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
24. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
Ardizzoni A; Fusco V; Pennucci C; Baldini E; Orsatti M; Vitale V; Bonavia M; Baracco F; Mereu C; Rosso R
Anticancer Res; 1991; 11(2):681-4. PubMed ID: 1648333
[TBL] [Abstract][Full Text] [Related]
25. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up.
Ueoka H; Kiura K; Tabata M; Kamei H; Gemba K; Sakae K; Hiraki Y; Hiraki S; Segawa Y; Harada M
Cancer; 1998 Jul; 83(2):283-90. PubMed ID: 9669811
[TBL] [Abstract][Full Text] [Related]
26. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group.
Work E; Nielsen OS; Bentzen SM; Fode K; Palshof T
J Clin Oncol; 1997 Sep; 15(9):3030-7. PubMed ID: 9294465
[TBL] [Abstract][Full Text] [Related]
27. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
Pujol JL; Douillard JY; Rivière A; Quoix E; Lagrange JL; Berthaud P; Bardonnet-Comte M; Polin V; Gautier V; Milleron B; Chomy F; Chomy P; Spaeth D; Le Chevalier T
J Clin Oncol; 1997 May; 15(5):2082-9. PubMed ID: 9164221
[TBL] [Abstract][Full Text] [Related]
28. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.
Feld R; Evans WK; Coy P; Hodson I; MacDonald AS; Osoba D; Payne D; Shelley W; Pater JL
J Clin Oncol; 1987 Sep; 5(9):1401-9. PubMed ID: 3040923
[TBL] [Abstract][Full Text] [Related]
29. Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation.
Videtic GM; Truong PT; Dar AR; Yu EW; Stitt LW
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):709-16. PubMed ID: 14529775
[TBL] [Abstract][Full Text] [Related]
30. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial.
Thatcher N; Qian W; Clark PI; Hopwood P; Sambrook RJ; Owens R; Stephens RJ; Girling DJ
J Clin Oncol; 2005 Nov; 23(33):8371-9. PubMed ID: 16293867
[TBL] [Abstract][Full Text] [Related]
31. [Small cell lung cancer: a retrospective analysis of results of chemotherapy and combined modality treatment].
Ohnoshi T; Hiraki S; Ueoka H; Kawahara S; Numata T; Nishii K; Yonei T; Yamashta H; Kiura K; Kozuka A
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1341-8. PubMed ID: 2543304
[TBL] [Abstract][Full Text] [Related]
32. Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study.
Gregor A; Drings P; Burghouts J; Postmus PE; Morgan D; Sahmoud T; Kirkpatrick A; Dalesio O; Giaccone G
J Clin Oncol; 1997 Aug; 15(8):2840-9. PubMed ID: 9256127
[TBL] [Abstract][Full Text] [Related]
33. Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients.
Wolf M; Pritsch M; Drings P; Hans K; Schroeder M; Flechtner H; Heim M; Hruska D; Mende S; Becker H
J Clin Oncol; 1991 Apr; 9(4):614-24. PubMed ID: 1648598
[TBL] [Abstract][Full Text] [Related]
34. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.
Roth BJ; Johnson DH; Einhorn LH; Schacter LP; Cherng NC; Cohen HJ; Crawford J; Randolph JA; Goodlow JL; Broun GO
J Clin Oncol; 1992 Feb; 10(2):282-91. PubMed ID: 1310103
[TBL] [Abstract][Full Text] [Related]
35. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
[TBL] [Abstract][Full Text] [Related]
36. Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA; Bacchi M; Hürny C; Bernhard J; Cerny T; Martinelli G; Leyvraz S; Senn HJ; Stahel R; Siegenthaler P
Ann Oncol; 1995 Feb; 6(2):157-66. PubMed ID: 7786823
[TBL] [Abstract][Full Text] [Related]
37. Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial.
Blackstock AW; Bogart JA; Matthews C; Lovato JF; McCoy T; Livengood K; Ho C; White D; Atkins JN; Miller AA
Clin Lung Cancer; 2005 Mar; 6(5):287-92. PubMed ID: 15845179
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
[TBL] [Abstract][Full Text] [Related]
39. [Small cell lung carcinoma: role of thoracic irradiation and its timing in relation to chemotherapy].
Payne DG; Murray N; Warde P
Bull Cancer; 1994 Feb; 81(2):119-28. PubMed ID: 7894117
[TBL] [Abstract][Full Text] [Related]
40. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.
Pujol JL; Daurès JP; Rivière A; Quoix E; Westeel V; Quantin X; Breton JL; Lemarié E; Poudenx M; Milleron B; Moro D; Debieuvre D; Le Chevalier T
J Natl Cancer Inst; 2001 Feb; 93(4):300-8. PubMed ID: 11181777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
